Brief: FDA Accepts Intercept's New Drug Application For Oca For The Treatment Of Pre-Cirrhotic Liver Fibrosis Due To Nash
19/01/2023 13:08
Jan 19 (Reuters) - Intercept Pharmaceuticals Inc
ICPT.O :
* FDA ACCEPTS INTERCEPT’S NEW DRUG APPLICATION FOR OCA FOR
THE
TREATMENT OF PRE-CIRRHOTIC LIVER FIBROSIS DUE TO NASH
* INTERCEPT PHARMACEUTICALS INC - PDUFA TARGET ACTION DATE
SET FOR
JUNE 22, 2023
Source text for Eikon: ID:nGNX9RbNrw
Further company coverage: ICPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intercept Pharmaceuticals
See all newsIntercept Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Huntington Ingalls Industries, Workday
U.S. RESEARCH ROUNDUP-Docusign, Immunovant, Liberty Energy
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
U.S. STOCKS ON THE MOVE-BullFrog AI, Soleno,